Barclays Maintains Overweight on Jazz Pharmaceuticals, Raises Price Target to $225

Benzinga Newsdesk www.benzinga.com Positive 78.2%

Neg 0% Neu 0% Pos 78.2%

Barclays analyst Etzer Darout maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Overweight and raises the price target from $224 to $225.